BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 23702928)

  • 21. Development of the peripheral sympathetic nervous system in zebrafish.
    Stewart RA; Look AT; Kanki JP; Henion PD
    Methods Cell Biol; 2004; 76():237-60. PubMed ID: 15602879
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging importance of ALK in neuroblastoma.
    Azarova AM; Gautam G; George RE
    Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recent advances in neuroblastoma research].
    Imaizumi M
    Seikagaku; 2004 May; 76(5):453-6. PubMed ID: 15212235
    [No Abstract]   [Full Text] [Related]  

  • 24. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
    Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
    Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma.
    Morandi F; Frassoni F; Ponzoni M; Brignole C
    J Immunol Res; 2018; 2018():8097398. PubMed ID: 30510968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic susceptibility to neuroblastoma.
    Tolbert VP; Coggins GE; Maris JM
    Curr Opin Genet Dev; 2017 Feb; 42():81-90. PubMed ID: 28458126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
    Owens C; Irwin M
    Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
    Epstein LF; Chen H; Emkey R; Whittington DA
    J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
    Cheung NK; Zhang J; Lu C; Parker M; Bahrami A; Tickoo SK; Heguy A; Pappo AS; Federico S; Dalton J; Cheung IY; Ding L; Fulton R; Wang J; Chen X; Becksfort J; Wu J; Billups CA; Ellison D; Mardis ER; Wilson RK; Downing JR; Dyer MA;
    JAMA; 2012 Mar; 307(10):1062-71. PubMed ID: 22416102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model.
    Nakagawara A; Ohira M
    Cancer Lett; 2004 Feb; 204(2):213-24. PubMed ID: 15013220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting ALK in neuroblastoma--preclinical and clinical advancements.
    Carpenter EL; Mossé YP
    Nat Rev Clin Oncol; 2012 May; 9(7):391-9. PubMed ID: 22585002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic lymphoma kinase: signalling in development and disease.
    Palmer RH; Vernersson E; Grabbe C; Hallberg B
    Biochem J; 2009 May; 420(3):345-61. PubMed ID: 19459784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].
    Pérel Y; Valteau-Couanet D; Michon J; Lavrand F; Coze C; Bergeron C; Notz A; Plantaz D; Chastagner P; Bernard F; Thomas C; Rubie H
    Arch Pediatr; 2004 Jul; 11(7):834-42. PubMed ID: 15234382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic mutations of ALK in neuroblastoma.
    Ogawa S; Takita J; Sanada M; Hayashi Y
    Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK pERKs up MYCN in neuroblastoma.
    Lindner S; Henssen A; Astrahantseff K; Schulte JH
    Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition.
    Reiff T; Huber L; Kramer M; Delattre O; Janoueix-Lerosey I; Rohrer H
    Development; 2011 Nov; 138(21):4699-708. PubMed ID: 21989914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche.
    Pietras A; Gisselsson D; Ora I; Noguera R; Beckman S; Navarro S; Påhlman S
    J Pathol; 2008 Mar; 214(4):482-8. PubMed ID: 18189331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic strategies for the treatment of neuroblastoma.
    Izbicka E; Izbicki T
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1200-14. PubMed ID: 16370386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell death-based treatment of neuroblastoma.
    Valter K; Zhivotovsky B; Gogvadze V
    Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroblastoma pathogenesis: deregulation of embryonic neural crest development.
    Tomolonis JA; Agarwal S; Shohet JM
    Cell Tissue Res; 2018 May; 372(2):245-262. PubMed ID: 29222693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.